drugset / Trial / NCT00334126

Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia

NCT00334126

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy (effectiveness of drug) and safety of the antipsychotic paliperidone ER compared to another antipsychotic, quetiapine, and to placebo in patients who are acutely ill with symptoms of schizophrenia.

Timeline

Start
2006-04
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Paliperidone Unknown 9 mg Oral
Subject Paliperidone Unknown 12 mg Oral
Subject Quetiapine Small molecule 600 mg Oral
Subject Quetiapine Small molecule 800 mg Oral

Indications